KRAS wt Allele clinical trials at UC Health
1 research study open to eligible people
Savolitinib in Treating Participants With MET Amplified Metastatic or Unresectable Colorectal Cancer
open to eligible people ages 18 years and up
This phase II trial studies how well savolitinib works in treating participants with MET amplified colorectal cancer that has spread to other places in the body or cannot be removed by surgery. Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
at UC Davis